Johnson & Johnson’s Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Controversial Prasad leaving FDA, NYT reports
- DGRO vs. HDV: Which BlackRock iShares Dividend ETF Pays More Income?
- Johnson & Johnson confirms FDA approval of Tecvayli-Darzalex Faspro combination
- FDA approves J&J’s Tec-Dara for multiple myeloma
- Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)